BLA 761171 · Y-Mabs Therapeutics INC
Danyelza
Naxitamab-Gqgk · Intravenous · Glycolipid Disialoganglioside-directed Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Nov 25, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
0 Phase 3, 12 recruiting
FAERS reports
250
191 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFUSION-RELATED REACTIONS and NEUROTOXICITY WARNING: SERIOUS INFUSION-RELATED REACTIONS and NEUROTOXICITY See full prescribing information for complete boxed warning Serious Infusion-Related Reactions: DANYELZA can cause serious infusion reactions, including cardiac arrest, anaphylaxis, hypotension, bronchospasm, and stridor. Premedicate prior to each DANYELZA infusion as recommended. Reduce the rate, interrupt infusion, or permanently discontinue DANYELZA based on severity ( 2.2 , 2.3 , 4 , 5.1 ). Neurotoxicity: DANYELZA can cause severe neurotoxicity, including severe neuropathic pain, transverse myelitis, and reversible posterior leukoencephalopathy syndrome (RPLS). Premedicate to treat neuropathic pain as recommended. Permanently discontinue DANYELZA based on the adverse reaction and severity ( 2.2 , 2.3 , 5.2 ). Serious Infusion-Related Reactions DANYELZA can...
What it is approved for
From the label in effect Aug 7, 2026.
DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). DANYELZA is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Naxitamab-gqgk binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, naxitamab-gqgk was able to bind to cell surface GD2 and induce complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 25, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- DANYELZA · NAXITAMAB-GQGK 40MG/10ML · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Naxitamab" as an intervention, any sponsor and status, largest first.
- Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk NeuroblastomaActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT01757626 · 186 participants · Start Dec 2012 · Primary completion Dec 2026
Drug: Hu3F8 With GM-CSF; Hu3F8 With GM-CSF · For: Neuroblastoma
Sites: New York, New York
- Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowPivotal-lookingActive, not recruiting
Y-mAbs TherapeuticsIndustry
NCT03363373 · 122 participants (planned) · Start Apr 3, 2018 · Primary completion Jun 30, 2026
Drug: GM-CSF + Naxitamab · For: Neuroblastoma
Sites: Indianapolis, Indiana; New York, New York; Toronto, Canada · 20 sites in all
Sun Yat-Sen University Cancer CenterAcademic, hospital or other
NCT06013618 · 120 participants (planned) · Start Jun 19, 2023 · Primary completion Dec 31, 2026
Drug: Naxitamab monotherapy; GM-CSF and 5 more · For: Neuroblastoma
Sites: Guangzhou, China
Giselle ShollerAcademic, hospital or other
NCT07932808 · 101 participants (planned) · Start Nov 26, 2026 · Primary completion Nov 26, 2031
Drug: Naxitamab and GM-CSF in combination with irinotecan and temozolomide; Dinutuximab. Immunotherapy and 1 more · For: Neuroblastoma
Sites: Hershey, Pennsylvania
Giselle ShollerAcademic, hospital or other
NCT06540963 · 98 participants (planned) · Start Dec 6, 2024 · Primary completion Dec 1, 2030
Drug: Tipifarnib; Naxitamab · For: Neuroblastoma
Sites: Little Rock, Arkansas; Hartford, Connecticut; Miami, Florida · 12 sites in all
Giselle ShollerAcademic, hospital or other
NCT05489887 · 93 participants (planned) · Start Sep 14, 2022 · Primary completion Sep 2029
Drug: Naxitamab · For: Neuroblastoma
Sites: Birmingham, Alabama; Little Rock, Arkansas; Oakland, California · 26 sites in all
- Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaCompleted
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT02650648 · 85 participants · Start Jan 5, 2016 · Primary completion Jul 28, 2025
Drug: cyclophosphamide; NK cells and 2 more · For: Neuroblastoma; High-Risk
Sites: New York, New York
SciClone PharmaceuticalsIndustry
NCT06047535 · 62 participants (planned) · Start Oct 31, 2023 · Primary completion Jun 15, 2027
Drug: Naxitamab · For: Neuroblastoma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypotension66
- pain64
- hypertension33
- urticaria31
- off label use29
- pyrexia27
- rash27
- bronchospasm18
- abdominal pain17
- oxygen saturation decreased17
- hypoxia15
- tachycardia15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 47 |
| 2022 | 47 |
| 2023 | 26 |
| 2024 | 55 |
| 2025 | 49 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.
Mora J, Chan GCF, Morgenstern DA, et al. · Nat Commun 2025 · Clinical Trial, Phase II, Multicenter Study
- A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission.
Kushner BH, Modak S, Mauguen A, et al. · Clin Cancer Res 2025 · Clinical Trial, Phase II
- Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.
Kushner BH, Modak S, Mauguen A, et al. · J Hematol Oncol 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
- A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.
Kushner BH, Modak S, White C, et al. · Int J Cancer 2026 · Clinical Trial, Phase II, Research Support, U.S. Gov't, P.H.S.
- Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.
Cheung IY, Cheung NV, Modak S, et al. · J Clin Oncol 2021 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Comparative evidence on the independent contribution of granulocyte-macrophage colony-stimulating factor to anti-GD2 immunotherapy in neuroblastoma: a systematic review and gap analysis.
Wieczorek A, Mielecka-Jarmocik G, Synakiewicz A, et al. · Front Oncol 2026 · Systematic Review
Sponsor: Y-Mabs Therapeutics INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.